La catena delle opzioni mostra i dati chiave delle opzioni azionarie di IGC Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per IGC Pharma..

IGC Pharma (AMEX:IGC) Azioni, Catena delle Opzioni

IGC PHARMA INC

IGC Pharma

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Pre-Market Outlook

PRGS

QMCO

VERO

XCUR

Mentre i mercati USA si muovono, alcuni titoli sono già sotto i riflettori. Analisi delle azioni da monitorare oggi.

Progress Software, Exicure e altre 3 azioni da tenere d&#39;occhio oggi

IGC Pharma Inc

INTEGRATED CYBR SOLUTIONS by INTEGRATED CYBER SOLUTIONS INC.

Integrated Cyber Solutions Inc

TCW Corporate Bond ETF

BlackRock Ishares Plc Is Global Crp Bnd ETF USD Hedged (Acc)

Biotech

News

Press Releases

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Penny Stocks

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

AN2 Therapeutics

Aytu BioPharma

CalciMedica

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Hyperion DeFi

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

NewcelX

NRX Pharmaceuticals

PolyPid

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

SCYNEXIS

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Tvardi Therapeutics

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ascendiant Capital

Alliance Global Partners

India Globalization Cap

Screenshot 2024-05-08 at 6.04.45 PM

General

OSUKF

6.7 Million Americans Live With Alzheimer&#39;s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings

Screenshot 2024-03-19 at 5.39.00 PM

IGC Pharma Advances In Alzheimer&#39;s Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1

Comments

IGC Pharma

IGC Pharma (IGC) Opzioni

IGC Pharma (AMEX:IGC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO